Sign in
4

Changes in Ownership

Allogene Therapeutics, Inc. Filed Acc 0001209191-19-043755

Chief Technical Officer sold 48,827 shares at an average $29.44 ($1,437,603)

  • Chief Technical Officer acquired 48,827 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
MOORE ALISON Chief Technical Officer 2019-07-26 Option exercise +13,193 $2.27 $29,948 78,566 D: show line 1 in the form
MOORE ALISON Chief Technical Officer 2019-07-26 Sale −13,193 $29.18 $384,994 65,373 D: show line 2 in the form
MOORE ALISON Chief Technical Officer 2019-07-29 Option exercise +23,815 $2.27 $54,060 89,188 D: show line 3 in the form
MOORE ALISON Chief Technical Officer 2019-07-29 Sale −23,815 $29.39 $699,870 65,373 D: show line 4 in the form
MOORE ALISON Chief Technical Officer 2019-07-30 Option exercise +11,819 $2.27 $26,829 77,192 D: show line 5 in the form
MOORE ALISON Chief Technical Officer 2019-07-30 Sale −11,819 $29.85 $352,738 65,373 D: show line 6 in the form
Open-market sales · 48,827 sh · avg $29.44 · $1,437,603

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
MOORE ALISON Chief Technical Officer 2019-07-26 Option exercise · Stock Option (Right to Buy) −13,193 802,663 D: show line 7 in the form
MOORE ALISON Chief Technical Officer 2019-07-29 Option exercise · Stock Option (Right to Buy) −23,815 778,848 D: show line 8 in the form
MOORE ALISON Chief Technical Officer 2019-07-30 Option exercise · Stock Option (Right to Buy) −11,819 767,029 D: show line 9 in the form
Loading xslF345X03/doc4.xml…